<DOC>
	<DOC>NCT01797913</DOC>
	<brief_summary>assess the efficacy and safety of gemcitabine in the maintenance treatment of advanced non-small cell lung cancer</brief_summary>
	<brief_title>The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>18~75 years Patients who were diagnosed by the histologic, cytologic diagnosis of IIIbIV nonsmall cell lung cancer patients who have acceptted combination chemotherapy based on platinum 4 course,SD OR PR,the CR patients should accept 6 course of combination chemotherapy. 3~8 weeks after patients complete first line chemotherapy(include radiotherapy) Ecog02 Expected life time longer than 3 monthes Normal laboratory values: leucocyte ≥ 4×109/L neutrophil ≥ 1.5×109/L platelet ≥ 100×109/L Hemoglobin ≥ 10g/L ALT and AST ≤ 2.5×ULN (≤ 5×ULN if liver metastasis) Signed written informed consent Patients have used drugs according to protocol Uncontrolled infection of Bacterial or virus or fungal Patients with other malignant tumor Uncontrolled brain metastases Female patients during their pregnant and lactation period, or patients without contracep</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>